Triggering Haematological Adoptive T-cell Immunotherapy Strategies by HUnting Novel T-cell receptors

Informazioni relative al progetto

THAT IS HUNT

ID dell’accordo di sovvenzione: 752717

DOI 10.3030/752717

Progetto chiuso

Data della firma CE 24 Marzo 2017

Data di avvio 1 Gennaio 2018

Data di completamento 31 Dicembre 2019

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale € 168 277,20

Contributo UE € 168 277,20

Coordinato da

OSPEDALE SAN RAFFAELE SRL
Italia

Obiettivo

Recent encouraging clinical results obtained with engineered T lymphocytes and increasing advances in the genome editing
field, have opened new opportunities for T-cell receptor (TCR) gene therapy as an immunotherapeutic approach for cancer.
Unfortunately, the broad applicability of this treatment is still hampered by the possible mispairing of exogenous/endogenous
TCR chains and by the limited number of high avidity tumor-specific TCRs. While the first issue has been successfully
addressed by the hosting lab with the development a TCR gene editing protocol, the identification of novel tumor-specific
TCRs is urgently required and this is the aim of my research proposal. We have the unique opportunity to combine the highly
complementary expertise of the hosting lab in T-cell biology/genetic transfer and of the applicant on immune repertoire
sequencing. We will target acute myeloid leukemia (AML) and hypothesize that by exploiting intrinsic features of AML (i.e.
ability of AML blasts to differentiate into potent antigen presenting cells expressing tumor antigens), the functional fingerprint
induced by AML on tumor-reactive T-cells, and cutting-edge technologies (i.e. next generation sequencing; ligandome
landscape analysis), we will provide a comprehensive immunoprofiling of tumor-specific T-cells and isolate tumor TCR
specificities. Results obtained in this study will streamline TCR hunting studies in solid tumors, leading to the generation of a
TCR library for different antigens and HLA restrictions, thus rendering TCR gene editing an innovative off-the-shelf
treatment available for a high number of cancer patients. Awarding this fellowship will greatly enhance researcher’s career
not only by providing the opportunity to widen scientific knowhow and acquire new skills, but also by enabling the researcher
to address a major bottleneck currently limiting the full exploitation of the rapidly growing field of cancer immunotherapy.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• scienze mediche e della salute › biotecnologia medica › ingegneria genetica › terapia genica
• scienze mediche e della salute › medicina di base › immunologia › immunoterapia
• scienze mediche e della salute › medicina clinica › oncologia › leucemia
• scienze naturali › scienze biologiche › genetica › genomi

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Argomento(i)

• MSCA-IF-2016 - Individual Fellowships

Invito a presentare proposte

H2020-MSCA-IF-2016

Meccanismo di finanziamento

MSCA-IF-EF-SE -

Coordinatore

OSPEDALE SAN RAFFAELE SRL

• Contributo netto dell'UE: € 168 277,20
• Indirizzo: VIA OLGETTINA 60 ; 20132 Milano ; Italia
• Regione: Nord-Ovest › Lombardia › Milano
• Tipo di attività: Entità private a scopo di lucro (esclusi istituti di istruzione secondaria o superiore)
• Costo totale: € 168 277,20